Title: A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine and Rituximab (BR) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation (CRISTALLO) Study Director: Hoffmann-La Roche Description: Investigators are conducting a phase 3 study to compare venetoclax plus obinutuzumab with rituximab-based regimens in fit patients with previously untreated chronic lymphocytic leukemia (CLL) without del(17p) or TP53 mutation.  Tri ..read more

An article published in Annals of Oncology described the design of a phase 3 sequential multiple assignment randomized trial (SMART) for the evaluation of multistage ibrutinib-based treatment approaches for previously untreated older patients with chronic lymphocytic leukemia (CLL). Although the efficacy and safety of the ibrutinib in patients with CLL has been demonstrated, most patients receive continuous treatment until disease progression. However, deeper responses potentially achieved with ibrutinib-based combination regimens (eg, involving CD20 inhibitors, such as rituximab and obinutuzu ..read more